Company profile
UK company 08219473, incorporated on 18 September 2012.
Perspectum | Perspectum
Perspectum delivers cutting-edge digital technologies that help clinicians provide better care for patients with liver disease, diabetes, and cancer.
Company number 08219473
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
The company has been set-up to rapidly translate liver imaging techniques designed in the university into clinical products used on patients. To date the company has been capitalised via the private sector and has won a Technology Strategy Board grant. It has continued to survive and grow and now employs ~50 people. It has FDA (US regulator) clearance to sell its products in the USA. It has a US office and sales team. It continues to develop IP, win competitive grants and sell into the market place. For more information http://perspectum-diagnostics.com/ or use google!
In March 2014 Perspectum won a Technology Strategy Board grant valued at around £1.2M. In march 2015, Perspectum won a contract with Galectin Therapeutics as part of their phase 2 trial. In June 2015, Perspectum achieved ISO 9001 In July 2015, Perspectum won a Horizon 2020 phase 1 grant to develop their products for children and adolescents with chronic liver disease. In Nov 2015, Perspectum added FDA clearance to its CE-marked product which allows it to sell into the important US clinical market. Perspectum Diagnostics was founded in partnership with the University of Oxford in 2012 after a ground-breaking study demonstrated the potential of T1 mapping to predict liver fibrosis. Dr Rajarshi Banerjee, then a clinical researcher at the University and now CEO of Perspectum Diagnostics, explains: "Magnetic Resonance Imaging in the liver is not a new concept. Research in the 1980's showed that there was some correlation between T1 values and liver disease. However, the liver has a tendency to store iron in quantities that are sufficient to alter the T1 signal, rendering it ineffective in many cases. Together with Prof Matthew Robson and other scientists at the Oxford Centre for Cardiovascular Magnetic Resonance Research, we developed our now patented technology which uses multiple parametric measurements to correct for differences in iron storage. This enabled the creation of our novel liver inflammation and fibrosis (LIF) score which correlates closely with the current gold standard of staging fibrotic liver disease, liver biopsy. We also found that the technique is particularly good at spotting early disease, which is essential in allowing patients to make lifestyle alterations before they progress to potentially irreversible cirrhosis. As a physician, I wanted to bring this technology to clinicians worldwide, helping them to slow the huge burden of liver disease. In 2012, we took the decision to commercialise the technology (branded as LiverMultiScan) and Perspectum Diagnostics was created. " Since its initial release in 2015, LiverMultiScan has achieved CE and FDA certification and has been installed on four continents. Using this remarkable technology, we have analysed more than 6000 images, and partnered with pharmaceutical companies in both clinical and preclinical trials. A recent study suggested that the technology predicts clinical outcomes in patients with chronic liver disease Why not be part of the next chapter of the Perspectum story?
1 Jan 2021 to 30 Jun 2022
Collaboration between the academic and commercial sectors will be vital for the future of healthcare. Increasingly we are moving towards using software tools that combine the results of many different measurements and tests. This creates a comprehensive, overall picture of disease in an individual patient. These sophisticated tools provide valuable suppor...
1 Sep 2020 to 30 Nov 2022
This project aims to improve the clinical care of patients with liver tumours. By developing state-of-the-art tools that integrate genetic, radiology and pathology information we expect to improve the diagnosis and characterisation of tumours, and inform the selection of therapeutic options. This has the potential to improve clinical outcomes for the pati...
1 Sep 2020 to 31 Aug 2023
Liver disease is an epidemic with up to four in ten people having health problems from their liver not working properly. A proportion of these patients develop scarring that is most commonly picked up late but which can progress without stopping to complete liver failure. It is one of the UK's largest health challenges for which we do not have answers. At...
1 Aug 2019 to 31 Jan 2022
To develop the economic analysis that will persuade clients to incorporate a new diagnostic tool into the clinical diagnostic pathway for liver disease.
1 Jul 2019 to 31 Mar 2021
Biliary diseases are hard to diagnose and monitor, resulting in patient anxiety. There is an increasing incidence of biliary diseases, due in part to increasing levels of obesity, leading to increasing incidence of mortality. To date, there are no biomarkers for biliary diseases. We aim to redress this situation via a novel quantitative imaging technology...
1 Apr 2019 to 31 Mar 2022
"There has been a surge in incidence of the metabolic syndrome, a cluster of conditions including obesity, increased blood pressure and Type 2 diabetes (T2D), which increase the risk of fatty liver disease, steatohepatitis, heart disease and stroke. Multiple interacting organs are involved, primarily the pancreas, liver, spleen, kidneys and heart. Though ...
1 Feb 2019 to 31 Mar 2023
"The London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare will improve NHS patient care and health outcomes, reduce healthcare costs and support the growth of companies, supporting the economy. It will do this by applying artificial intelligence technologies to medical imaging (for example MRI scans, CT scans PET scans and ul...
1 Jan 2019 to 31 Dec 2019
"This project aims to improve the standard care of patients with Autoimmune Hepatitis (AIH). AIH is a chronic inflammatory disease of the liver of unknown cause that, if untreated, can lead to liver failure, and death. Whislt there is an effective treatment with steriods and medicines that supress the immune system, these are not perfect, with many patien...
1 Jan 2019 to 31 Mar 2023
"We have formed a consortium of collaborating hospitals and commercial companies with public and patient involvement and input from charities to enable us to work with the public and the NHS to best develop and test the use of Artificial Intelligence programmes to improve health care. We are working with university academics and NHS hospitals across the c...
1 Jan 2019 to 31 Mar 2023
"PathLEAD (**Path**ology data **L**akes, **E**ducation, **A**nalytics and **D**iscovery) is a consortium of nationally leading experts from the teaching hospitals of Coventry, Belfast, Nottingham and Oxford, their associated Universities and Philips, the commercial partner. We will develop computer aided diagnostics for testing of pathology samples. Speci...
1 Feb 2017 to 31 Mar 2019
This project aims to improve the surgical care of patients with primary and secondary liver cancer. It will do this by developing a new product that uses medical imaging to measure the health of a patient’s liver, helping doctors personalise their treatment plans to individual patients. Liver surgery is the treatment of choice for curing cancer in the liv...
1 Jul 2016 to 31 Mar 2019
To develop new algorithms to create the vital bioinformatic and statistical platform for a novel MRI-based method to determine fat, iron, inflammation/fibrosis in the liver.
